artenimol has been researched along with Liver Diseases, Alcoholic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bian, M; Chen, A; Chen, X; Jin, H; Kai, J; Lu, C; Shao, J; Yao, Z; Zhang, C; Zhang, F; Zheng, S | 1 |
| Lu, C; Shao, J; Xu, W; Yao, L; Zhang, F; Zheng, S | 1 |
2 other study(ies) available for artenimol and Liver Diseases, Alcoholic
| Article | Year |
|---|---|
Dihydroartemisinin inhibits ER stress-mediated mitochondrial pathway to attenuate hepatocyte lipoapoptosis via blocking the activation of the PI3K/Akt pathway.
Topics: Animals; Apoptosis; Artemisinins; Chromones; Endoplasmic Reticulum Stress; Ethanol; Hepatocytes; Lipid Metabolism; Liver Diseases, Alcoholic; Male; Mice; Mice, Inbred ICR; Mitochondria; Morpholines; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Signal Transduction | 2018 |
Dihydroartemisinin protects against alcoholic liver injury through alleviating hepatocyte steatosis in a farnesoid X receptor-dependent manner.
Topics: Animals; Artemisinins; Fatty Liver, Alcoholic; Liver Diseases, Alcoholic; Male; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear | 2017 |